

December 13, 2022

**British Columbia Securities Commission**

Dear Sirs / Mesdames:

**Re: Moss Genomics Inc.**

We refer to the non-offering prospectus of Moss Genomics Inc. (the "Company") dated December 13, 2022.

We consent to being named and to the use, in the above-mentioned non-offering prospectus, of our report dated December 13, 2022 to the directors of the Company on the following financial statements:

Statements of financial position as at June 30, 2021 and 2020;

Statements of loss and comprehensive loss, changes in shareholders' deficiency, and cash flows for the years ended June 30, 2021 and 2020, and a summary of significant accounting policies and other explanatory information.

We report that we have read the non-offering prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in a prospectus, which does not constitute an audit or review of the non-offering prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours very truly,

*s/ "Davidson & Company LLP"*

**DAVIDSON & COMPANY LLP**

Chartered Professional Accountants

